David J Sermer MD

PubMed

• 2 citations
  Pre-existing cardiovascular disease is associated with an increased risk of cardiovascular events during Bruton tyrosine kinase inhibitor therapy.
  Maria J Fernandez Turizo, Eunice Kim, Cancan Zhang, Tuyen Yankama, Gottfried Von Keudell
  The Oncologist. 2025-02-06
• 9 citations
  Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia.
  Jorge J Castillo, Andrew R Branagan, David Sermer, Catherine A Flynn, Kirsten Meid
  Blood. 2024-02-15
• 4 citations
  Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma.
  Hoa Van Le, Kim Van Naarden Braun, Grzegorz S Nowakowski, David Sermer, John Radford
  Leukemia & Lymphoma. 2023-03-01

Journal Articles

• Oncology Drug Development and Approval of Systemic Anticancer Therapy by the US Food and Drug Administration  
  Martell RE, Sermer D, Getz K, Kaitin K, The Oncologist, 2013
• Acrofacial Dysostosis Syndrome Type Rodriguez: Prenatal Diagnosis and Autopsy Findings  
  Sermer D, Quercia N, Chong K, Chitayat D, American Journal of Medical Genetics, 2007

Abstracts/Posters

• Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of ...
  David Sermer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019